Gattefossé expands its offer with the launch of three new pharmaceutical excipients

Launching three ingredients in the same year is unusual in the pharmaceutical ingredient industry, given the long and complex research & development and regulatory demands that are placed on the developer. But once completed, new ingredients can successfully and safely address many formulation challenges that are present in the industry.

To ensure their international launches and successes, Labrafac™ MC60, Gelucire® 59/14 and Emulfree® Duo conform to all regulatory requirements.

Labrafac™ MC60 is used to enhance oral bioavailability of poorly water-soluble and poorly permeable drugs. It acts as a solubilizer and intestinal permeation enhancer for a wide variety of molecules.

Labrafac™ MC60 can successfully be used in lipid-based Type I (oily solutions) and Types II and III (SEDDS) formulations.

Gelucire® 59/14 is a self-emulsifying excipient used for oral bioavailability enhancement of poorly water-soluble drugs, thanks to its high solubilization capacity. Upon contact with aqueous or digestive media, it spontaneously forms a fine dispersion.

Gelucire® 59/14 is supplied in pellets, making it easy to handle and an interesting addition to Gattefossé's Gelucire® range of products. A key difference to other Gelucire® grades is its higher melting point.

Emulfree® Duo is the new functional excipient developed by Gattefossé. It is dedicated to topical drugs and medications which are applied on the body or to mucosal areas.

As a mixture of excipients, Emulfree® Duo is a ready-to-use PEG-free system. It has been designed to stabilize the oil phase within a bi-gel by ensuring fine and homogeneous dispersions in the aqueous phase. This new excipient offers unique and innovative textures in formulations while improving treatments and patient adherence.